{"id":"NCT02115113","sponsor":"Novartis Pharmaceuticals","briefTitle":"REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy","officialTitle":"Multicenter, Prospective, Open-label, Controlled, Randomized, Parallel Groups Study to Evaluate the Renal Function of Adult Liver Transplant Recipients Treated With Two Everolimus-based Immunosuppressive Regimens (Tacrolimus Withdrawal vs. Minimization) Until 12 Months Post-transplant, With a 6-months Follow-up","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03-28","primaryCompletion":"2016-09-30","completion":"2016-09-30","firstPosted":"2014-04-15","resultsPosted":"2019-02-28","lastUpdate":"2019-02-28"},"enrollment":78,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Liver Transplantation"],"interventions":[{"type":"DRUG","name":"Everolimus","otherNames":[]},{"type":"DRUG","name":"Tacrolimus","otherNames":[]}],"arms":[{"label":"Group A (Tacrolimus Elimination Arm)","type":"EXPERIMENTAL"},{"label":"Group B (Tacrolimus Minimization Arm)","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was, starting from the Italian clinical practice in liver transplantation, to optimize the immunosuppressive therapy, considering specific patient characteristics as alcoholic cirrhosis, hepatitis C virus (HCV), hepatocellular carcinoma (HCC), and short/long-term implications. Then efficacy and safety of a calcineurin inhibitor (CNI)-withdrawal regimen was evaluated in comparison with a CNI-minimization regimen.","primaryOutcome":{"measure":"Renal Function Assessed by Estimated Glomerular Filtartion Rate (eGFR)","timeFrame":"At 12 months post-transplant","effectByArm":[{"arm":"Group A (Tacrolimus Elimination Arm)","deltaMin":85.5,"sd":3.97},{"arm":"Group B (Tacrolimus Minimization Arm)","deltaMin":80.26,"sd":3.87}],"pValues":[{"comp":"OG000 vs OG001","p":"0.3013"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":14,"countries":["Italy"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":25,"n":78},"commonTop":["Pyrexia","Transaminases increased","Nausea","Anaemia","Leukopenia"]}}